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Abstract 
Background: Oral lichen planus (OLP) is a T cell mediated immune response. T cells locally present in the involved 
tissues release cytokines like interleukin-6 (IL-6), which contributes to pathogenesis of OLP. Also IL-6 has been 
associated with multidrug resistance protein (MRP) expression by keratinocytes. Correspondingly, upregulation of 
MRP was found in OLP. We conducted this study to evaluate the effects of various drugs on serum IL-6 in OLP; and 
correlation of these effects with the nature of clinical response and resistance pattern seen in OLP lesions with various 
therapeutic modalities. Thus we evaluated the role of serum IL-6 in deciding therapy for multidrug resistant OLP. 
Material and Methods: Serum IL-6 was evaluated in 42 erosive OLP (EOLP) patients and 10 normal mucosa and 
10 oral squamous cell carcinoma cases using ELISA technique. OLP patients were randomly divided into 3 groups 
of 14 patients each and were subjected to Pimecrolimus local application, oral Mycophenolate Mofetil (MMF) 
and Methotrexate (MTX) alongwith Pimecrolimus local application. IL-6 levels were evaluated before and after 
treatment. 
Results: Serum IL-6 levels were raised above 3pg/ml in 26.19% erosive OLP (EOLP) cases (mean- 3.72±8.14). 
EOLP (5%) cases with IL-6 levels above 5pg/ml were resistant in MTX group. However significant decrease in 
serum IL-6 corresponding with the clinical resolution was seen in MMF group. 
Conclusions: Significantly raised IL-6 levels in EOLP reflect the chronic inflammatory nature of the disease. As 
serum IL-6 levels significantly decreased in MMF group, correspondingly no resistance to treatment was noted. 
However with MTX there was no significant decrease in IL-6 and resistance to treatment was noted in some, espe-
cially plaque type lesions. Thus IL-6 can be a possible biomarker in deciding the best possible therapy for treatment 
resistant OLP. 
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sive agents.
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Introduction
Lichen planus (LP) is a chronic inflammatory disease 
that affects skin and mucosa (1). Oral forms of lichen 
planus (OLP) are more common, chronic and recalci-
trant than cutaneous type causing pain and discomfort 
leading to significant impairment of quality of life (2).
Because LP is a result of T cell mediated immune res-
ponse, T cells locally present in the involved epithelial 
and subepithelial tissues (3) release proinflammatory 
cytokines including interleukin-6 (IL-6) and interleu-
kin-8 (IL-8) (4,5). Levels of interleukins in the serum 
and saliva in OLP are considered a reliable indicator of 
therapeutic response on molecular basis (6-8). Also IL-6 
has growth factor properties, suggesting its role in the 
development and progression of cancer (8).
Keratinocytes in OLP present major histocompatibi-
lity complex (MHC) class II antigens to CD4+ T cells 
causing secretion of Th1 cytokines interleukin-2 and 
interferon-γ. These cytokines in turn activate the CD8+ 
T cells causing keratinocyte apoptosis via tumour necro-
sis factor- α (TNF- α). Also TNF-α enhances  the acti-
vation of nuclear factor-κB in the subepithelial T cells 
and as a consequence leads to the increased expression 
of other proinflammatory cytokines including IL-6 (4,5). 
IL-6 has been associated with multidrug resistance pro-
tein (MRP) expression by the keratinocytes (9) and has 
been demonstrated by some to play a role in the oral 
cancer pathogenesis (7,10).
This disease probably represents a cell mediated immu-
nologic response to an induced antigenic change in the 
mucosa of predisposed individuals (1). Thus the use of 
immunomodulators or immunosuppressants to control 
the disease would appear reasonable. Although, Corti-
costeroids have been the mainstay of treatment for OLP 
since long, but there is no evidence of long term remis-
sion being established. Further corticosteroids are also 
associated with their own side effects (11).
Calcineurin inhibitors have been tried with good results 
in cases which are recalcitrant to corticosteroids and 
they have lesser side effects (12-14). Pimecrolimus 1% 
cream has been approved by the FDA for Atopic derma-
titis (15). It has been suggested to be effective in the ma-
nagement of symptoms and erosions of OLP (12,16,17). 
Pimecrolimus has a similar mode of action to that of Ta-
crolimus but is more selective with no effect on dendritic 
cells (15) and has been associated with better efficacy 
and side effect profile than Tacrolimus (12-14). Myco-
phenolate mofetil (MMF) has been tried with high suc-
cess rates in recalcitrant cases of erosive OLP (EOLP) 
and long term remission with safer side effect profile 
compared to other immunosuppesive drugs like Cyclos-
porine, Azathioprine and Corticosteroids has been re-
ported (18). Methotrexate (MTX) as a supplement with 
topical steroids also has shown success in resolving ero-
sive OLP cases recalcitrant to other common treatment 
modalities (19,10). To date there are few published stu-
dies regarding the efficacy of Pimecrolimus (17,20,21) 
and its comparison with other therapies in OLP (14) and 
fewer are available for MTX (20,21) and MMF in OLP 
(18,22-24) and have a limited sample size. We have con-
ducted a large scale study with 42 EOLP patients.  
As IL-6 has been associated with MRP expression by the 
keratinocytes with up regulation of MRP expression seen 
in the lichen planus lesions (9); hence we intended to eva-
luate the effects of various drugs on serum IL-6 and corre-
lation of these effects with the nature of clinical response, 
alongwith the resistance pattern seen in OLP lesions with 
various therapeutic modalities. Thus we evaluated the role 
of serum IL-6 in deciding therapy for multidrug resistant 
OLP. As of now, most of the studies with these drugs in 
OLP have focused on the clinical aspects of the disease 
only. But broad based interventions are required at mole-
cular level to assess the pathways involved in resistance 
to drugs and the therapeutic response. 
Material and Methods 
The proposed study was approved by the institutional 
ethical committee of Maulana Azad Institute of Dental 
Sciences (MAIDS); and was conducted in the department 
of Oral Medicine and Radiology, MAIDS, New Delhi, in 
association with department of Biochemistry, Maulana 
Azad Medical College. This study was a prospective, 
double blind, randomised clinical trial. Patients were se-
lected from the outpatient department of MAIDS; and 
those with histologically proven erosive oral lichen pla-
nus (EOLP) were included in the study. Patients selected 
were between the 19 and 72 years old, since OLP is an 
unusual disease in childhood. Patients were excluded 
from the study in cases of Lichenoid contact reaction 
due to any medication, mouthrinse, toothpaste or any 
other agent; any therapy for Lichen Planus or drugs as-
sociated with Lichenoid reaction within past 8 weeks; 
any malignant or viral involvement in mouth; pregnant 
or nursing women also excluded, patients not willing to 
participate in the study, patients whose complete follow 
up was lacking.                                                   
Patient selection was done based on the characteristic clini-
cal features of OLP (Bilateral reticular striae with atrophic 
erosive areas). Informed consent regarding the procedures 
being performed was taken from the patients selected. Pre-
treatment Biopsy from the representative area was done, 
for the confirmation of diagnosis with the characteristic 
histopathological findings of subepithelial dense lympho-
cytic infiltrate, basilar vacuolization with apoptosis leading 
to homogeneous eosinophilic civette bodies formation. 
Serum samples of the confirmed cases were collected for 
Enzyme linked immunosorbent assay (ELISA) to determi-
ne baseline serum levels of IL-6 (pg/ml). 
In this study 42 EOLP patients were enrolled. Mean age 
at presentation of EOLP was 46.95±11.96 (19-72) years. 
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Mean duration since when the lesions have been present 
was 21.293±20.77 (1-246) months. Male to female ratio 
was 8:7. Along with negative control group of 10 normal 
mucosa, of patients undergoing minor surgery as well 
as healthy volunteers; and positive control group of 10 
histopathologically proven Oral squamous cell carcino-
ma (OSCC) cases was selected for comparison of serum 
IL-6 levels, which were age and sex matched with the 
OLP group.
All the OLP cases were randomised into 3 treatment 
groups, each with 14 subjects. These groups were sub-
jected to 3 different types of treatments as 1) Pimecro-
limus, 2) Mycophenlate Mofetil (MMF) with Pimecro-
limus and 3) Methotrexate (MTX) with Pimecrolimus. 
All the patients were advised to stop any other drug 
treatment if taking for at least 8 weeks. Pimecrolimus 
was prescribed as 1% (w/w) topical aqueous gel form, 
four times daily, for 9 months, after meals and patient 
was advised not to drink and eat for at least ½ hour after 
topical application. MMF was prescribed as oral 1 gram 
daily dosase in 2 equally divided doses for 3 to 4 months 
depending upon the clinical response and 0.5 gram as 
once daily dosage for next 3 months; and patient was 
advised to take the drug empty stomach (1 hour before 
food or 2 hours after meals). MTX was prescribed as 
7.5 mg weekly dosage for 7-9 months depending upon 
the response. Patient was advised to take the drug empty 
stomach and to take with food if gastrointestinal distur-
bances occurred and was advised to avoid taking milk 
rich products alongwith drug. Laboratory tests were per-
formed for estimation of liver function, kidney function, 
haemoglobin (Hb) level, platelet count at beginning of 
treatment in all the groups; and at a regular interval of 15 
days, in both the groups subjected to systemic treatment 
with MMF and MTX. Platelet count below 1 lakh and 
Hb levels below 10 mg/dl was considered an indication 
to taper the drugs. Post- treatment serum samples were 
collected for serum IL-6 estimation at the end of six 
months of treatment, in each case. 
-Collection of samples: Approximately 2 mL of blood 
was collected by venipuncture and placed into a serum 
separator tube. The blood sample was allowed to clot for 
30 minutes before processing the serum. After centrifu-
gation for 10 minutes at approximately 3000g, the serum 
was decanted into a new 5-mL vial and stored at -70ºC 
until analyzed. 
-Estimation of serum IL-6 levels (ELISA):  IL-6 con-
centration in the collected serum samples was determi-
ned by ELISA using commercially obtained ELISA kits 
(KRISHGHEN BioSystems). Briefly the procedure was 
as follows: (1) IL-6 working standard and dilution series 
prepared. (2) 100 μL of assay diluents added to each well 
(3) 100 mL of standard or sample added and incubated 
for 2 hours; (4) 200 mL of IL-6 conjugate added and 
incubated for 2 hours; (5) 200 mL of substrate solution 
added and incubated for 20 minutes; (6) 50 mL of stop 
solution added. Data were read at 450/550 nm (EL 808; 
Bio-tek Instrument, Winooski, VT) and results were ex-
pressed as pg/mL. Photon output was considered pro-
portional to IL-6 concentration and IL-6 concentration 
was being evaluated from standard curve.
Comparison of serum IL 6 levels pre and post treatment 
along with comparison among different groups (EOLP 
Vs. Negative control, EOLP Vs. Positive control) and 
subgroups (Treatment groups- pre Vs. Post-treatment 
and among various treatment groups) has been done. 
-Statistical analysis plan: Because some variables in the 
study groups were not normally distributed, nonparame-
tric statistics were applied. Only two-sided probability 
values less than .05 were considered as significant. The 
data were entered in software (SPSS 13 for windows, 
SPSS Inc, Chicago, III). Continuous data were reported 
as mean ± SD. A Kruskal-Wallis test was carried out for 
multiple comparisons, while Mann-Whitney tests were 
performed to detect a difference between each pair of 
groups in rank sign. Intra group comparison of various 
parameters at different points of time (Pre and post 
treatment difference of various markers) was done by 
using Wilcoxon signed rank test. 
Results
Interleukin 6 levels were found to be raised above 3pg/
ml (upper limit of normal range detected in this study) in 
only 26.19% of the EOLP cases with mean of 3.72±8.14. 
IL6 levels of EOLP were found to be significantly di-
fferent from negative control (P<0.05- Mann-Whitney 
U test). Pre and post-treatment levels were significantly 
different in MMF group only (P<0.05- Mann-Whitney 
U test). Serum IL6 levels in OSCC were not found to be 
elevated above 3pg/ml (Table 1). 
By Wilcoxon signed rank test a significant decrease was 
noted in serum IL6 levels after treatment in MMF group; 
while no significant decrease in serum IL6 levels was 
noted in Pimecrolimus and Methotrexate groups (Ta-
ble 2). In this study 5% of the EOLP cases with IL-6 
levels above 5pg/ml were resistant to treatment with 
MTX supplemented with Pimecrolimus. In a case with 
IL-6 levels of 6.45 pg/ml, eruption of skin lesions as 
well as aggravation of oral lesions was noted while on 
MTX therapy which did not resolve even after continued 
treatment with MTX for 45 days.
-Side effect profile 
Regarding safety profile a significant decrease in platelet 
count was seen in some patients in MTX group at 3-4th 
months period requiring tapering of the drug for a pe-
riod of about 15 days-1 month based upon restoration of 
count although there was no significant change in liver 
and kidney function profile and there was no gastrointes-
tinal upset during use. MMF was well tolerated in all the 
cases and there was no complaint of nausea, vomiting 
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Group Interleukin 6 levels (Mean and Median)
Negative control/Healthy(n-10)* 1.72±1.52
1.87(0.5-3)
Positive control/OSCC (n-10)# 0.37±0.36
0.26(0-1.02)
Oral Lichen Planus (n-60) 3.72±8.14
1.28(0-49.71)
Pretreatment Post-treatment
Pimecrolimus group 4.23±10.81
1.44 (0-49.71)
2.33±4.88
0.90(0.22-22.54)
MMF group** 2.14±2.42
1.28(0-8.42)
0.71±0.89
0.45(3.70-3.93)
MTX group 4.79±8.89
0.90(0-38.78)
2.83±5.81
0.49(0.22-24.12)
Table 1. Serum IL-6 levels (pg/ml).
* IL-6 levels of erosive oral lichen planus cases were found to be significantly different from negative 
control (P<0.05- Mann-Whitney U test). **Pre and post-treatment levels were significantly different 
in MMF group only (P<0.05- Mann-Whitney U test). #Serum IL-6 levels in OSCC were not found to 
be elevated above 3pg/ml. MTX: Methotrexate, MMF: Mycophenolate Mofetil, OSCC: Oral squamous 
cell carcinoma, IL-6: interleukin-6.
Treatment Group Serum Interleukin 6 levels [pg/ml 
(Pre-post)]
Pimecrolimus 1.89±11.81
.34(20.94  47.21)
(P=.173)#
MMF group 1.43±2.64
.41(-1.81 – 8.19)
(P=.009)*
MTX group 1.96±11.30
0.22(-22.00 -37.87)
(P=.247)#
Table 2. Difference pre to post-treatment IL6.
*By Wilcoxon signed rank test a significant decrease was noted in 
serum IL-6 levels after treatment in MMF group. # no significant 
decrease in serum IL-6 levels after treatment. MTX: Methotrexate, 
MMF: Mycophenolate Mofetil, IL-6: Interleukin-6.
and diarrhoea and kidney and liver function profile was 
stable. Although transient burning sensation was noted 
with Pimecrolimus during application in initial 15-20 
days of treatment but it was not a hindrance to treatment 
and patient compliance.
Discussion
IL-6 levels were found to be raised in only 26.19% of the 
EOLP cases (mean: 3.72±8.14 pg/ml) compared to nor-
mal mucosa (mean: 1.72±1.52) in our study; which was 
statistically significant (P<0.05). This finding is suppor-
ted by previous studies, where significantly increased 
serum IL-6 levels were noted in OLP (P<0.05) (6,24); 
where raised serum IL-6 levels were reported by Sun et 
al. (6)  in only 15% of the EOLP cases (mean 3.4±3.2 
pg/ml) and by Yamamoto et al. (24) in 50% of EOLP 
cases with IL-6 levels above 40 pg/ml in some cases. 
This finding reflects the chronic inflammatory nature of 
the disease (25). Although raised serum IL-6 levels in 
OLP have also been suggested to reflect its malignant 
potential (7). 
Lichen planus is assumed to represent a delayed hyper-
sensitivity reaction, in the course of which cytokines, 
including IL-6, control the proliferation and differentia-
tion of cytotoxic T lymphocytes which attack the epider-
mis and cause apoptosis of the undifferentiated kerati-
nocytes (26).
IL-6, a pleiotropic cytokine with varied systemic 
functions, plays a major role in inflammatory processes 
as a host immune defense mechanism (27). However, 
increased or deregulated expression of IL-6 significantly 
contributes to the pathogenesis of various human disea-
ses including OLP. Numerous preclinical and clinical 
studies have revealed the pathological roles of the IL-6 
pathway in inflammation, autoimmunity, and cancer. 
Based on the rich body of studies on biological activities 
of IL-6 and its pathological roles, therapeutic strategies 
targeting the IL-6 pathway are in development for can-
cers, inflammatory and autoimmune diseases (28). 
In our study a significant decrease was noted in serum 
IL-6 levels after treatment in MMF group (P=0.009) 
(Table 2). This may suggest the involvement of IL-6 in 
EOLP as shown by the previous studies (4,9,26) and tar-
geting of IL-6 pathway by MMF with a possible role 
of IL-6 in assessing the therapeutic response. Nagy et 
al. (29) reported a significant decrease in production of 
IL-6 after MMF intervention, which accords with our 
findings. Similar decrease in IL6 with other treatments 
was noted in other studies (6,7).
Decrease in IL-6 levels may have a significant role to 
play in clinical resolution of the sign and symptoms 
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associated with OLP as it has been found that stimula-
tion of the normal human epidermal keratinocytes and 
primary human dermal fibroblasts with IL-6 results in 
an upregulation of MRP expression and activity (9). 
Correspondingly, upregulation of MRP expression was 
found in the lesional skin taken from the patients with 
lichen planus (9).
In this study 5% of the OLP cases have shown serum 
IL-6 levels above 5pg/ml and were resistant to MTX 
therapy; finding supported a previous study, where resis-
tance to MTX was reported (20). These findings may ne-
cessitate the finding of promising alternative treatments 
for patients with multidrug resistance predicted with 
measurement of serum IL-6 levels having a possible role 
in guiding the therapy.
Serum IL-6 levels in OSCC were not found to be ele-
vated (Table 1), finding supported by a previous study 
(24); although serum IL-6 has been found to be raised in 
other body cancers where anti IL-6 monoclonal antibody 
therapy has been useful in the treatment of cancer (27). 
Contrary to our finding some clinical studies have re-
ported increase in serum IL-6 levels in OSCC (7). Thus 
further studies are required to establish the role of IL-6 
in OSCC and so in OLP to evaluate its malignant poten-
tial in this context. 
So, comparison of various therapeutic modalities for 
OLP regarding their effects on serum IL-6 levels reveals 
that there is a marked possibility for these markers to help 
decide the best possible therapy for a case, which after 
this study is proposed to be MTX supplemented with Pi-
mecrolimus and a possible role of MMF supplemented 
with topical therapy in cases recalcitrant to MTX. 
Conclusions
Significantly raised serum IL-6 levels in OLP reflect 
the chronic inflammatory nature of the disease and that 
serum IL-6 can be a possible biomarker in deciding the 
best possible therapy for treatment resistant EOLP and 
in therapeutic monitoring. However further studies are 
required to establish the role of IL-6 in OSCC and so in 
OLP to evaluate its malignant potential in this context.
References
1. Carrozzo M, Uboldi de Capei M, Dametto E, Fasano ME, Arduino 
P, Broccoletti R, et al. Tumor necrosis factor-alpha and interferon-ga-
mma polymorphisms contribute to susceptibility to oral lichen planus. 
J Invest Dermatol. 2004;122:87-94. Erratum in: J Invest Dermatol. 
2004;123:805.
2. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thon-
gprasom K. Current controversies in Oral lichen planus: report of an 
international concensus meeting. Part 2. Clinical management and ma-
lignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol 
Endod. 2005;100:164-78.
3. Ishii T. Immunohistochemical demonstration of T cell subsets and 
accessory cells in Oral lichen planus. J Oral Pathol Med. 1987;16:356-
61.
4. Gu GM, Martin MD, Darveau RP, Truelove E, Epstien J. Oral and 
Serum IL-6 levels in oral lichen planus patients. Oral Surg Oral Med 
Oral Pathol Radiol Endod. 2004;98:673-8.
5. Zhang Y, Lin M, Zhang S, Wang Z, Jiang L, Shen J, et al. NF-
kappaB-dependent cytokines in saliva and serum from patients with 
oral lichen planus: a study in an ethnic Chinese population. Cytokine. 
2008;41:144-9.
6. Sun A, Chia JS, Chang YF, Chiang CP. Serum interleukin-6 level 
is a useful marker in evaluating therapeutic effects of levamisole and 
Chinese medicinal herbs on patients with oral lichen planus. J Oral 
Pathol Med. 2002;31:196-203.
7. Nibali L, Fedele S, D’Aiuto F, Donos N. Interleukin-6 in oral disea-
ses: a review. Oral Dis. 2012;18:236-43.
8. Nishimoto N. Interleukin-6 as a therapeutic target in candidate infla-
mmatory diseases. Clin Pharmacol Ther. 2010;87:483-7.
9. Dreuw A, Hermanns HM, Heise R, Joussen S, Rodríguez F, Mar-
quardt Y, et al. Interleukin-6-type cytokines upregulate expression of 
multidrug resistance-associated proteins in NHEK and dermal fibro-
blasts. J Invest Dermatol. 2005;124:28-37.
10. Gasche C, Reinisch W, Huber WD, Leshinsky-Silver E, Levine A, 
Abdul-Baki H, et al. IL-10RA truncation mutations and Semite popu-
lations. Inflamm Bowel Dis. 2011;17:1438.
11. Silverman S Jr, Gorsky M, Lozada-Nur F, Giannotti K. A prospec-
tive study of findings and management in 214 patients with oral lichen 
planus. Oral Surg Oral Med Oral Pathol. 1991;72:665-70.
12. Ibrahim SS, Hazzaa HH. Topical pimecrolimus effect on Fas indu-
cing apoptosis in oral lichen planus, a clinical immunohistochemical 
study. J oral pathol Med. 2012;41:315-21.
13. Swift JC, Rees TD, Plemons JM, Hallmon WW, Wright JC. Wi-
lliam WH. Effectiveness of 1% pimecrolimus cream in the treatment 
of oral erosive lichen planus. J Periodontol. 2005;76:627-35.
14. Gorouhi F, Solhpour A, Beitollahi JM, Afshar S, Davari P, Has-
hemi P, et al. Randomised trial of pimecrolimus cream versus triam-
cinolone acetonide paste in the treatment of lichen planus. J Am Acad 
Dermatol. 2007;57:806-13.
15. Allen BR1, Lakhanpaul M, Morris A, Lateo S, Davies T, Scott 
G, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus 
cream 1% in atopic dermatitis patients. Arch Dis Child. 2003;88:969-
73.
16. Volz T, Caroli U, Lüdtke H, Bräutigam M, Kohler-Späth H, Röc-
ken M, et al. Pimecrolimus cream 1% in erosive oral lichen planus--a 
prospective randomized double-blind vehicle-controlled study. Br J 
Dermatol. 2008;159:994.
17. McCaughey C, Machan M, Bennett R, Zone JJ, Hull CM. Pime-
crolimus 1% cream for oral erosive lichen planus: a 6-week randomi-
zed, double-blind, vehicle-controlled study with a 6-week open-label 
extension to assess efficacy and safety. J Eur Acad Dermatol Venereol. 
2011;25:1061-7.
18. Frieling U, Bonsmann G, Schwarz T, Luger TA, Beissert S. 
Treatment of severe lichen planus with mycophenolate mofetil. J Am 
Acad Dermatol. 2003;49:1063-6.
19. Nylander Lundqvist E, Wahlin YB, Hofer PA. Methotrexate su-
pplemented with steroid ointments for the treatment of severe erosive 
lichen ruber. Acta Derm Venereol. 2001;82:63-4.
20. Torti DC, Jorizzo JL, McCarty MA. Oral lichen planus: a case se-
ries with emphasis on therapy. Arch Dermatol. 2007;143:511-5.
21. Kanwar AJ, De D. Methotrexate for treatment of lichen planus: old 
drug, new indication. J Eur Acad Dermatol Venereol. 2013;27:410-3.
22. Dalmau J, Puig L, Roé E, Peramiquel L, Campos M, Alomar A. 
Successful treatment of oral erosive lichen planus with mycophenolate 
mofetil. J Eur Acad Dermatol Venereol. 2007;21:259-60.
23. Wee J S, Shirlaw PJ, Challacombe SJ, Setterfield JF. Efficacy of 
mycophenolate mofetil in severe mucocutaneous lichen planus: a re-
trospective review of 10 patients. Br J Dermatol. 2012;167:36-43.
24. Yamamoto T, Yoneda K, Ueta E, Hirota J, Osaki T. Serum cytokine 
levels in patients with oral mucous membrane disorders. J Oral Pathol 
Med. 1991;20:275-9.
25. Karagouni EE, Dotsika EN, Sklavounou A. Alteration in peripheral 
blood mononuclear cell function and serum cytokines in oral lichen 
planus. J Oral Pathol Med. 1994;23:28-35.
26. Fayyazi A, Schweyer S, Soruri A, Duong LQ, Radzun HJ, Pe-
ters J, et al. T lymphocytes and altered keratinocytes express inter-
J Clin Exp Dent. 2015;7(4):e477-82.                                                                                                                                              Interleukin-6 in multidrug resistant oral lichen planus 
e482
feron-gamma and interleukin 6 in lichen planus. Arch Dermatol Res. 
1999;291:485-90.
27. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pa-
thway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904-
10.
28. Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, et al. 
Targeting interleukin-6 in inflammatory autoimmune diseases and can-
cers. Pharmacol Ther. 2014;141:125-39.
29. Nagy SE, Andersson JP, Andersson UG. Effect of mycophenolate 
mofetil (RS-61443) on cytokine production: inhibition of superanti-
gen-induced cytokines. Immunopharmacology. 1993;26:11-20.
Acknowledgements
Financial support to the study was provided by Indian Council of Me-
dical Research. There are no other conflicts of interest. The Authors 
thank Mr. Rajesh Ahuja, ex- senior scientist at AIIMS for statistical 
analysis and Dr. Sudeshana for technical assistance in the study.
